Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients.

Int J Cancer · 2026 · PMC12875174 · PMID 41175040

Europe PMC DOI

hedged sentence

0.1040

closest p · 2.1× alpha

0.1040

boldest claim

The sentences

showed a trendp = .104not close (p > 0.1)

While not significant, Class 2 showed a trend towards better CA‐125 response ( p = .104, Figure 3E ). 3.6.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.